INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 October 2018 (11.10.2018) WIPO I PCT D IV °nolo iflo oimIE (10) International Publication Number WO 2018/184966 Al (51) International Patent Classification: C07K 16/30 (2006.01) A61K 39/00 (2006.01) A61K 47/68 (2017.01) (21) International Application Number: PCT/EP2018/058043 (22) International Filing Date: 29 March 2018 (29.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17164466.9 03 April 2017 (03.04.2017) EP (71) Applicant (for all designated States except US): F. HOFF- MANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH). (71) Applicant (for US only): HOFFMANN-LA ROCHE INC. [US/US]; Overlook at Great Notch, 150 Clove Road, 8th Floor, Suite 8 - Legal Department, Little Falls, New Jer- sey 07424 (US). (72) Inventors: HOFER, Thomas; c/o Roche Glycart AG, Wagistrasse 18, 8952 Schlieren (CH). KOENIG, Maximil- iane; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). MOESSNER, Ekkehard; c/o Roche Gly- cart AG, Wagistrasse 18, 8952 Schlieren (CH). NIE- WOEHNER, Jens; c/o Roche Diagnostics GmbH, Non- nenwald 2, 82377 Penzberg (DE). WEINZIERL, Tina; c/ o Roche Glycart AG, Wagistrasse 18, 8952 Schlieren (CH). LARIVIERE, Laurent; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) 1-1 71 00 - 1-1 00 1-1 O (74) Agent: CUENI, Leah; Grenzacherstrasse 124, 4070 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (54) Title: ANTIBODIES BINDING TO STEAP-1 (57) : The present invention generally relates to antibodies that bind to STEAP-1, including bispecific antigen binding mole- cules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
ANTIBODIES BINDING TO STEAP-1